Goldman Sachs Group Inc An2 Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.93 - $3.76 $377,922 - $736,264	195,815 Added 690.22%	224,185 $481,000
Q1 2024 May 15, 2024	BUY	$2.78 - $21.53 $39,820 - $308,395	14,324 Added 101.98%	28,370 $92,000
Q4 2023 Feb 13, 2024	BUY	$13.92 - $21.0 $195,520 - $294,966	14,046 New	14,046 $287,000
Q2 2023 May 14, 2024	BUY	$5.06 - $9.91 $126,808 - $248,354	25,061 Added 178.42%	39,107 $332,000
Q2 2023 Aug 14, 2023	BUY	$5.06 - $9.91 $197,881 - $387,550	39,107 New	39,107 $332,000
Q2 2022 Aug 15, 2022	SELL	$7.7 - $18.82 $150,126 - $366,933	-19,497 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $292,455 - $300,253	19,497 New	19,497 $294,000

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $20.8M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.